Trinity Biotech


Market Cap: 26.7M


About: Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

Employees: 380

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

130% more capital invested

Capital invested by funds: $2.58M [Q4 2023] → $5.95M (+$3.37M) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

2.39% less ownership

Funds ownership: 3.94% [Q4 2023] → 1.55% (-2.39%) [Q1 2024]

27% less funds holding

Funds holding: 26 [Q4 2023] → 19 (-7) [Q1 2024]

54% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 13

92% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 12

Research analyst outlook

We haven’t received any recent analyst ratings for TRIB.

Financial journalist opinion